OmniSeq News

Schoenborn named CEO at OmniSeq

June 26, 2019 Buffalo News - OmniSeq Inc., a molecular diagnostic laboratory on the Buffalo Niagara Medical Campus, has a new CEO. Margot P. Schoenborn, formerly the company's chief administrative officer, has been promoted to the position.

read more

People in the News

June 26, 2019 GenomeWeb - OmniSeq announced today that it has appointed Margot Schoenborn to succeed Mark Gardner as the firm's CEO.

read more

Margot Schoenborn becomes CEO of fast-growing OmniSeq

Business First - Margot Schoenborn has quite the resume. Now she gets to add yet another interesting professional experience: biotech boss. Schoenborn has been named the CEO of OmniSeq, which develops and sells molecular diagnostic tests that show cancer patients what...

read more
OmniSeq & LabCorp Launch OmniSeq Advance℠ Assay

OmniSeq & LabCorp Launch OmniSeq Advance℠ Assay

New test combines both targeted therapy and immune-oncology biomarkers in a single test with 99% actionability, providing benefits for the treatment of patients and the development of new therapies.ASCO, CHICAGO, ILLINOIS – June 1, 2018 – OmniSeq® , a CAP accredited,...

read more

OmniSeq & LabCorp Launch Tumor-Only MSI NGS Assay

BUFFALO, NEW YORK – April 16, 2018 – OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global life sciences company, announced today the commercial launch of OmniSeq MSI NGS, a tumor-only,...

read more

Follow Us on Twitter

Learn how @OmniSeq contributes to the @RoswellPark Comprehensive Cancer Center's discovery of blood-based biomarkers that predict response to immune checkpoint inhibitor therapy in this recent @NatureComms article:

Check out how @OmniSeq and @RoswellPark are leveraging comprehensive immune profiling to identify potentially actionable targets for #mmunotherapy in pancreatic cancer. Download it here:
#Pancreatic #oncology #PrecisionMedicine

.@OmniSeq is partnering with the University of Pittsburgh Medical Center to employ a gene expression assay investigating the potential for personalized immunotherapy combinations for patients with head and neck squamous cell carcinoma. | @UPMC

In case you missed it! OmniSeq's webinar," Comprehensive Genomic and Immune Profiling to Support Drug Development" is now available to view at you convenience.
Just click:
@illumina @ClinicalOMICs @Labcorp

FEBRUARY 9, 2021. 8:00 am PT, 11:00 am ET, 17:00 CET. REGISTR NOW to learn how @OmniSeq utilizes Genomic and Immune Profiling to support drug discovery.
@illumina @ClinicalOMICs @Labcorp

Load More...